The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya.
COVID-19
Measles
Outbreak
Supplementary immunisation activities
Vaccination coverage
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
03 02 2021
03 02 2021
Historique:
received:
14
10
2020
accepted:
11
01
2021
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
12
2
2021
Statut:
epublish
Résumé
The COVID-19 pandemic has disrupted routine measles immunisation and supplementary immunisation activities (SIAs) in most countries including Kenya. We assessed the risk of measles outbreaks during the pandemic in Kenya as a case study for the African Region. Combining measles serological data, local contact patterns, and vaccination coverage into a cohort model, we predicted the age-adjusted population immunity in Kenya and estimated the probability of outbreaks when contact-reducing COVID-19 interventions are lifted. We considered various scenarios for reduced measles vaccination coverage from April 2020. In February 2020, when a scheduled SIA was postponed, population immunity was close to the herd immunity threshold and the probability of a large outbreak was 34% (8-54). As the COVID-19 contact restrictions are nearly fully eased, from December 2020, the probability of a large measles outbreak will increase to 38% (19-54), 46% (30-59), and 54% (43-64) assuming a 15%, 50%, and 100% reduction in measles vaccination coverage. By December 2021, this risk increases further to 43% (25-56), 54% (43-63), and 67% (59-72) for the same coverage scenarios respectively. However, the increased risk of a measles outbreak following the lifting of all restrictions can be overcome by conducting a SIA with ≥ 95% coverage in under-fives. While contact restrictions sufficient for SAR-CoV-2 control temporarily reduce measles transmissibility and the risk of an outbreak from a measles immunity gap, this risk rises rapidly once these restrictions are lifted. Implementing delayed SIAs will be critical for prevention of measles outbreaks given the roll-back of contact restrictions in Kenya.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has disrupted routine measles immunisation and supplementary immunisation activities (SIAs) in most countries including Kenya. We assessed the risk of measles outbreaks during the pandemic in Kenya as a case study for the African Region.
METHODS
Combining measles serological data, local contact patterns, and vaccination coverage into a cohort model, we predicted the age-adjusted population immunity in Kenya and estimated the probability of outbreaks when contact-reducing COVID-19 interventions are lifted. We considered various scenarios for reduced measles vaccination coverage from April 2020.
RESULTS
In February 2020, when a scheduled SIA was postponed, population immunity was close to the herd immunity threshold and the probability of a large outbreak was 34% (8-54). As the COVID-19 contact restrictions are nearly fully eased, from December 2020, the probability of a large measles outbreak will increase to 38% (19-54), 46% (30-59), and 54% (43-64) assuming a 15%, 50%, and 100% reduction in measles vaccination coverage. By December 2021, this risk increases further to 43% (25-56), 54% (43-63), and 67% (59-72) for the same coverage scenarios respectively. However, the increased risk of a measles outbreak following the lifting of all restrictions can be overcome by conducting a SIA with ≥ 95% coverage in under-fives.
CONCLUSION
While contact restrictions sufficient for SAR-CoV-2 control temporarily reduce measles transmissibility and the risk of an outbreak from a measles immunity gap, this risk rises rapidly once these restrictions are lifted. Implementing delayed SIAs will be critical for prevention of measles outbreaks given the roll-back of contact restrictions in Kenya.
Identifiants
pubmed: 33531015
doi: 10.1186/s12916-021-01906-9
pii: 10.1186/s12916-021-01906-9
pmc: PMC7854026
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Subventions
Organisme : Medical Research Council
ID : MC_PC_19065
Pays : United Kingdom
Organisme : Medical Research Council, Department for International Development
ID : MR/S005293/1
Investigateurs
James D Munday
(JD)
Carl A B Pearson
(CAB)
Simon R Procter
(SR)
Oliver Brady
(O)
David Simons
(D)
Rachel Lowe
(R)
W John Edmunds
(WJ)
Katharine Sherratt
(K)
Rosanna C Barnard
(RC)
Alicia Rosello
(A)
Adam J Kucharski
(AJ)
Fiona Yueqian Sun
(FY)
Nikos I Bosse
(NI)
Petra Klepac
(P)
Yang Liu
(Y)
Kiesha Prem
(K)
Gwenan M Knight
(GM)
Akira Endo
(A)
Sam Abbott
(S)
Emily S Nightingale
(ES)
Thibaut Jombart
(T)
Jon C Emery
(JC)
Georgia R Gore-Langton
(GR)
Joel Hellewell
(J)
James W Rudge
(JW)
Hamish P Gibbs
(HP)
Kathleen O'Reilly
(K)
Kevin van Zandvoort
(K)
Yung-Wai Desmond Chan
(YD)
Damien C Tully
(DC)
Anna M Foss
(AM)
Christopher I Jarvis
(CI)
Katherine E Atkins
(KE)
Samuel Clifford
(S)
Matthew Quaife
(M)
Billy J Quilty
(BJ)
Rein M G J Houben
(RMGJ)
Rosalind M Eggo
(RM)
Graham Medley
(G)
Sophie R Meakin
(SR)
Timothy W Russell
(TW)
Nicholas G Davies
(NG)
Charlie Diamond
(C)
Arminder K Deol
(AK)
C Julian Villabona-Arenas
(CJ)
Stéphane Hué
(S)
Megan Auzenbergs
(M)
Quentin J Leclerc
(QJ)
Amy Gimma
(A)
Références
PLoS One. 2014 Aug 15;9(8):e104786
pubmed: 25127257
BMC Med. 2020 Oct 5;18(1):316
pubmed: 33012285
Lancet Glob Health. 2020 Oct;8(10):e1264-e1272
pubmed: 32687792
Clin Vaccine Immunol. 2012 Mar;19(3):396-400
pubmed: 22237896
J Infect Dis. 2011 Jul;204 Suppl 1:S343-52
pubmed: 21666183
Int J Infect Dis. 2014 Feb;19:103-5
pubmed: 24334025
Vaccine. 2018 Jan 2;36(1):170-178
pubmed: 29174680
Vaccine. 2018 Dec 18;36(52):7965-7974
pubmed: 30416017
Pan Afr Med J. 2018 Sep 28;31:65
pubmed: 31007812
PLoS One. 2018 Jul 2;13(7):e0199786
pubmed: 29965975
BMC Med. 2019 Sep 25;17(1):180
pubmed: 31551070
Science. 2015 Mar 13;347(6227):1240-2
pubmed: 25766232
Vaccine. 2018 Feb 28;36(10):1248-1255
pubmed: 29398276
J Res Med Sci. 2015 May;20(5):529-30
pubmed: 26487883
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Lancet Infect Dis. 2020 May;20(5):546
pubmed: 32311326
Lancet Infect Dis. 2019 Nov;19(11):1235-1245
pubmed: 31548079
Int J Epidemiol. 2010 Apr;39 Suppl 1:i48-55
pubmed: 20348126
Lancet Infect Dis. 2017 Dec;17(12):e420-e428
pubmed: 28757186